Currently out of the existing stock ratings of Wan Nurhayati, 5 are a HOLD (83.33%), 1 are a BUY (16.67%).

Wan Nurhayati

Work Performance Price Targets & Ratings Chart

Analyst Wan Nurhayati, currently employed at CFRA, has had 66.67% of price targets met with an average potential upside of 9.29%, reached in 60 days on average.

Wan Nurhayati has documented 12 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GSK, GlaxoSmithKline PLC ADR at 30-Oct-2025.

Wall Street Analyst Wan Nurhayati

Analyst best performing recommendations are on NVS (NOVARTIS AG ADR).
The best stock recommendation documented was for NVS (NOVARTIS AG ADR) on 10/29/2025. The price target of $126 was fulfilled within 13 days with a profit of $7.8 (6.6%), with a performance score of 5.08.

Average potential price target upside

NVO Novo Nordisk A/S NVS Novartis AG ADR GSK GlaxoSmithKline PLC ADR

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 14-May-2025

$40

$2.18 (5.76%)

$47

1 months 10 days ago
(12-Oct-2026)

14/27 (51.85%)

$1.42 (3.68%)

28

Hold Since 11-Sep-2026

$40

$2.18 (5.76%)

$40

2 months 11 days ago
(11-Sep-2026)

6/6 (100%)

$-3.07 (-7.13%)

32

Buy Since 20-Nov-2025

$62

5 months 5 days ago
(17-Jun-2026)

1/2 (50%)

$15.28 (32.71%)

210

Hold Since 03-Jun-2026

$47

$9.18 (24.27%)

$41

5 months 19 days ago
(03-Jun-2026)

3/6 (50%)

$5.53 (13.33%)

41

Buy Since 12-Dec-2022

$70

$32.18 (85.09%)

$70

9 months 19 days ago
(03-Feb-2026)

2/9 (22.22%)

$22.09 (46.11%)

211

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Wan Nurhayati?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?